Stryker (NYSE:SYK)‘s stock had its “hold” rating restated by equities research analysts at Needham & Company LLC in a research report issued on Friday, AnalystRatings.com reports.
Other equities analysts have also recently issued research reports about the stock. Oppenheimer reissued a “hold” rating and set a $215.00 target price on shares of Stryker in a research report on Friday. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating and set a $190.00 target price on the stock. in a research report on Monday, May 4th. Wells Fargo & Co lifted their target price on shares of Stryker from $201.00 to $205.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. UBS Group lowered their price target on shares of Stryker from $230.00 to $202.00 and set a “neutral” rating on the stock in a report on Friday, May 1st. Finally, Cfra lowered their price target on shares of Stryker from $234.00 to $231.00 and set a “strong-buy” rating on the stock in a report on Friday, May 1st. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Stryker presently has a consensus rating of “Buy” and an average price target of $216.25.
SYK stock opened at $193.30 on Friday. The company has a market capitalization of $72.45 billion, a P/E ratio of 28.10, a price-to-earnings-growth ratio of 3.36 and a beta of 0.84. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.77 and a current ratio of 2.58. Stryker has a 52-week low of $124.54 and a 52-week high of $226.30. The business has a 50-day simple moving average of $186.61 and a two-hundred day simple moving average of $189.31.
Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Stryker had a net margin of 11.38% and a return on equity of 20.53%. The firm had revenue of $2.76 billion for the quarter, compared to analysts’ expectations of $2.63 billion. As a group, sell-side analysts forecast that Stryker will post 6.26 earnings per share for the current fiscal year.
In other Stryker news, CFO Glenn S. Boehnlein sold 10,351 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $185.24, for a total value of $1,917,419.24. Following the sale, the chief financial officer now owns 16,321 shares in the company, valued at $3,023,302.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 7,299 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $193.23, for a total transaction of $1,410,385.77. Following the completion of the sale, the director now owns 13,972 shares in the company, valued at approximately $2,699,809.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,670 shares of company stock valued at $5,775,251. 6.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in SYK. Sofos Investments Inc. grew its holdings in Stryker by 160.0% in the first quarter. Sofos Investments Inc. now owns 728 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 448 shares during the period. Evolution Wealth Advisors LLC grew its holdings in Stryker by 64.4% in the second quarter. Evolution Wealth Advisors LLC now owns 143 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 56 shares during the period. WASHINGTON TRUST Co purchased a new stake in Stryker in the first quarter worth about $28,000. Filbrandt Wealth Management LLC purchased a new stake in shares of Stryker during the first quarter valued at approximately $30,000. Finally, Ballast Advisors LLC purchased a new stake in shares of Stryker during the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 71.24% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Article: Intrinsic Value
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.